Description

Tivozanib: Targeted Therapy for Advanced Kidney Cancer

What is Tivozanib?

Tivozanib is an oral medication used in the treatment of advanced renal cell carcinoma (RCC), a common type of kidney cancer. It belongs to a class of drugs known as tyrosine kinase inhibitors (TKIs) and works by targeting specific receptors involved in the growth of cancer cells and the development of blood vessels that supply tumors.

How Does Tivozanib Work?

Tivozanib selectively inhibits vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, and VEGFR-3). By blocking these receptors, Tivozanib reduces the formation of new blood vessels (angiogenesis), effectively starving the tumor of nutrients and slowing its growth. Its high selectivity may also result in fewer side effects compared to less targeted treatments.

Approved Uses

Tivozanib (brand name Fotivda) is approved for:

• The treatment of relapsed or refractory advanced renal cell carcinoma (RCC) in adults who have received two or more prior systemic therapies.

• It may also be considered in first-line settings for certain patients, based on clinical judgment and treatment guidelines.

Dosage and Administration

Tivozanib is typically administered as a 1.34 mg capsule taken once daily for 21 consecutive days, followed by a 7-day rest period, in 28-day treatment cycles. Dosage may be adjusted based on patient response and tolerability.

Common Side Effects

Some of the most frequently reported side effects of Tivozanib include:

• Hypertension (high blood pressure)

• Fatigue

• Diarrhea

• Decreased appetite

• Voice changes (dysphonia)

• Nausea

Patients are closely monitored for these and other potential adverse effects throughout treatment.

Benefits of Tivozanib

• High selectivity for VEGF receptors may reduce off-target side effects.

• Convenient oral dosing improves patient adherence.

• Clinically proven efficacy in patients with previously treated RCC.

• Often considered in patients intolerant to other TKIs or immunotherapies.

Who Should Not Take Tivozanib?

Tivozanib may not be suitable for individuals with:

• Severe cardiovascular conditions

• Recent bleeding events

• Pregnancy or breastfeeding

A healthcare provider will evaluate the risks and benefits before initiating treatment.

Final Thoughts

Tivozanib represents a significant advancement in the targeted therapy landscape for advanced kidney cancer, particularly for patients who have failed previous treatments. If you or a loved one has been diagnosed with renal cell carcinoma, consult your oncologist to determine if Tivozanib is the right option for your treatment plan.